Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weiguang Xue

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|May 23, 2015
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspectiveStephane A Régnier, William Malcolm, Jennifer Haig, et al.
Pharmacoeconomics|November 29, 2021
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence ModelsMin Huang, Scott Ramsey, Weiguang Xue, et al.
International Journal of Women'S Health|June 14, 2019
A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in GermanyWeiguang Xue, Adam Lloyd, Edel Falla, et al.
Journal of Cutaneous Medicine and Surgery|June 27, 2020
Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-AnalysisWeiguang Xue, Paranjoy Saharia, Emma Gray, et al.
Journal of Medical Economics|January 5, 2021
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a <i>MET</i> exon 14 skipping mutation in the United StatesBeilei Cai, Zheng-Yi Zhou, Weiguang Xue, et al.
Future Oncology (London, England)|August 21, 2023
Association between event-free survival and overall survival in early-stage triple-negative breast cancerMin Huang, Peter A Fasching, Amin Haiderali, et al.
Advances in Therapy|January 17, 2023
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United StatesMin Huang, Peter A Fasching, Amin Haiderali, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinicoeconomics and Outcomes Research : CEOR|May 23, 2015
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspectiveStephane A Régnier, William Malcolm, Jennifer Haig, et al.
Pharmacoeconomics|November 29, 2021
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence ModelsMin Huang, Scott Ramsey, Weiguang Xue, et al.
International Journal of Women'S Health|June 14, 2019
A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in GermanyWeiguang Xue, Adam Lloyd, Edel Falla, et al.
Journal of Cutaneous Medicine and Surgery|June 27, 2020
Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-AnalysisWeiguang Xue, Paranjoy Saharia, Emma Gray, et al.
Journal of Medical Economics|January 5, 2021
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a <i>MET</i> exon 14 skipping mutation in the United StatesBeilei Cai, Zheng-Yi Zhou, Weiguang Xue, et al.
Future Oncology (London, England)|August 21, 2023
Association between event-free survival and overall survival in early-stage triple-negative breast cancerMin Huang, Peter A Fasching, Amin Haiderali, et al.
Advances in Therapy|January 17, 2023
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United StatesMin Huang, Peter A Fasching, Amin Haiderali, et al.
Pageof 1